Journal of Cancer Prevention

Korean Society of Cancer Prevention (대한암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus

  • Choi, Ha-Neul (Department of Food and Nutrition, College of Natural Science, Changwon National University) ;
  • Yim, Jung-Eun (Department of Food and Nutrition, College of Natural Science, Changwon National University)
  • Received : 2018.11.19
  • Accepted : 2018.12.18
  • Published : 2018.12.30
⟨ Previous Next ⟩

Abstract

Background: Type 2 diabetes mellitus (T2DM) and cancer are serious health problems worldwide, and their prevalences have been on the rise in recent years. It has been reported that adropin plays an important role in the development of T2DM, oxidative stress, inflammation, and obesity. However, there is limited information available on T2DM from human studies, especially for the Korean population. In this study, we aimed to investigate the correlation between adropin levels and obesity of Korean T2DM patients. Methods: Thirty-six T2DM patients were recruited for this study. The participants were further classified into female (n = 12) and male (n = 24). Their body composition, metabolic parameters, inflammatory factors, and oxidative stress were measured. Results: The severity of obesity is more manifested in male than in female. Plasma triglyceride (TG) and high-sensitivity C-reactive protein (hs-CRP) levels of male were significantly higher than female. The plasma adropin and adiponectin level of female was significantly higher than male. The body weight, body mass index (BMI), body fat mass were negatively correlated with the plasma adropin level in female, whereas adropin has positive correlation with adiponectin in female. The hs-CRP was negatively correlated with the plasma adropin level in female and male. malondialdehyde, reactive oxidative species, and $TNF-{\alpha}$ was not significantly correlated with adropin in patients with T2DM. Conclusions: These findings suggest that adropin may be more used as a biomarker for predicting the risk of obesity and inflammation in Korean patients with T2DM, especially women.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-21. https://doi.org/10.3322/caac.20078
  2. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S13-27. https://doi.org/10.2337/dc18-S002
  3. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab 2011;96:1654-63. https://doi.org/10.1210/jc.2011-0585
  4. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003;58:335-41. https://doi.org/10.1179/acb.2003.58.6.001
  5. O'Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999;74:171-80. https://doi.org/10.4065/74.2.171
  6. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38. https://doi.org/10.1002/jbt.10058
  7. World Health Organization. Diabetes. http://www.who.int/newsroom/fact-sheets/detail/diabetes. Accessed November 15, 2017.
  8. Lee JW, Kang HT, Lim HJ, Park B. Trends in diabetes prevalence among Korean adults based on Korean National Health and Nutrition Examination Surveys III-VI. Diabetes Res Clin Pract 2018;138:57-65. https://doi.org/10.1016/j.diabres.2018.01.013
  9. Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int 2014;2014:461917.
  10. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91. https://doi.org/10.1038/nrc1408
  11. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33. https://doi.org/10.1126/science.1160809
  12. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7:507-16. https://doi.org/10.1038/nrendo.2011.77
  13. Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 2010;6:444-53. https://doi.org/10.1038/nrendo.2010.93
  14. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation 2010;122:S185-92. https://doi.org/10.1161/CIRCULATIONAHA.109.931782
  15. Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 2013;380:73-81. https://doi.org/10.1007/s11010-013-1660-4
  16. Sayin O, Tokgoz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2014;27:479-84.
  17. Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) 2012;20:1394-402. https://doi.org/10.1038/oby.2012.31
  18. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008;8:468-81. https://doi.org/10.1016/j.cmet.2008.10.011
  19. Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy 2016;117:100-5.
  20. Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci 2018;19:E1293. https://doi.org/10.3390/ijms19051293
  21. Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest 2016;39:747-54. https://doi.org/10.1007/s40618-016-0453-5
  22. Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol 2014;41:310-2.
  23. Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med 2013;41:375-80.
  24. Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin- a novel biomarker of heart disease: a systematic review article. Iran J Public Health 2016;45:1568-76.
  25. Shahjouei S, Ansari S, Pourmotabbed T, Zand R. Potential roles of adropin in central nervous system: review of current literature. Front Mol Biosci 2016;3:25.
  26. Nergiz S, Altinkaya SO, Kurt Omurlu I, Yuksel H, Kucuk M, Demircan Sezer S. Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol 2015;31:730-5. https://doi.org/10.3109/09513590.2015.1065480
  27. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013;5:1218-40. https://doi.org/10.3390/nu5041218
  28. Pitha J, Kovar J, Blahova T. Fasting and nonfasting triglycerides in cardiovascular and other diseases. Physiol Res 2015;64 Suppl 3:S323-30.
  29. Zang H, Jiang F, Cheng X, Xu H, Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index [published online ahead of print April 17, 2018]. Endocr J. doi: 10.1507/endocrj.EJ18-0060.
  30. Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med 2014;52:751-8.
  31. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014;63:3242-52. https://doi.org/10.2337/db14-0388
  32. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-91. https://doi.org/10.1146/annurev.physiol.68.033104.152158
  33. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51. https://doi.org/10.2119/2008-00058.Rabe
  34. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008;35:321-6. https://doi.org/10.1016/S1673-8527(08)60047-8
  35. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92. https://doi.org/10.1172/JCI29126
  36. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-senitizing adipocyte-derived protein. Diabetes 2002;51:2734-41. https://doi.org/10.2337/diabetes.51.9.2734
  37. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808. https://doi.org/10.1172/JCI200319246
  38. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007;56:16-23. https://doi.org/10.2337/db06-1076